# Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease

> **NCT00959972** · PHASE4 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 50 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** Varenicline
- **DRUG:** Transdermal Nicotine Patch

## Key facts

- **NCT ID:** NCT00959972
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959972, "Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00959972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*